Calendario›REGN›REGN7508 · ROXI-CAT-I

REGN7508 · ROXI-CAT-I

REGN7508 in Adult Participants for Prevention of Cancer-Associated Thrombosis

Ensayo de REGENERON PHARMACEUTICALS, INC. en Trombosis asociada al cancer (CAT).

Fase

Fase 3

Estado

Reclutando pacientes

Participantes

1.120

previstos

Centros

20

Fin del objetivo primario

ene 2030

estimado por el promotor

Qué significa cada fase y cada estado.

Estudio de intervención, aleatorizado, cuádruple ciego. Comenzó en mar 2026.

Qué mide

Tiempo hasta el primer evento de TEV adjudicado centralmente (TVP, EP) o TAE, o muerte relacionada con tromboembolismo o TAE (Through 6 months) (del registro, en inglés)

Cómo lo describe el promotor

En el documentoEn inglés, del registroThis study is researching an experimental drug called REGN7508 (called "study drug"). The study is focused on the prevention of Cancer-Associated Thrombosis (CAT) in participants. The aim of the study is to see how effective the study drug is in preventing blood clots in participants with solid tumors who are currently receiving anticancer treatment or planning to start anticancer treatment within a month of being assigned to a study treatment, or recovering from surgery, and how the study drug compares to placebo for CAT. The study is looking at several other research questions, including: * What side effects may happen from taking the study drug * How much study drug is in the blood at different times * Whether the body makes antibodies against the study drug (which could make the study drug less effective or could lead to side effects)

Más ensayos de REGN

Todos los de REGN, en su ficha.

Ficha completa en ClinicalTrials.gov (NCT07410117), actualizada en sep 2026.